Biomol Ther.
2017 Jul;25(4):345-353. 10.4062/biomolther.2016.126.
Production of Recombinant Anti-Cancer Vaccines in Plants
- Affiliations
-
- 1Department of Medicine, Therapeutic Protein Engineering Lab, College of Medicine, Chung-Ang University, Seoul 06974, Republic of Korea. ksko@cau.ac.kr
- KMID: 2386899
- DOI: http://doi.org/10.4062/biomolther.2016.126
Abstract
- Plant expression systems have been developed to produce anti-cancer vaccines. Plants have several advantages as bioreactors for the production of subunit vaccines: they are considered safe, and may be used to produce recombinant proteins at low production cost. However, several technical issues hinder large-scale production of anti-cancer vaccines in plants. The present review covers design strategies to enhance the immunogenicity and therapeutic potency of anti-cancer vaccines, methods to increase vaccine-expressing plant biomass, and challenges facing the production of anti-cancer vaccines in plants. Specifically, the issues such as low expression levels and plant-specific glycosylation are described, along with their potential solutions.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Plant factory: new resource for the productivity and diversity of human and veterinary vaccines
- Effects of Addition of Sugars on the Stability of Hepatitis B Virus Vaccine
- Immunogenicity and reactogenicity of a yeast recombinant DNA hepatitis B vaccine in healthy subjects
- Strategy for Novel Vaccine and Antivirals Against Foot-and-Mouth Disease
- Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer
